EPA:ALGEN - Euronext Paris - Matif - FR0004053510 - Common Stock - Currency: EUR
EPA:ALGEN (5/9/2025, 7:00:00 PM)
3.0595
+0.06 (+1.98%)
The current stock price of ALGEN.PA is 3.0595 EUR. In the past month the price increased by 4.06%. In the past year, price decreased by -26.45%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 18.27 | 295.07B | ||
AMG.DE | AMGEN INC | 13 | 128.98B | ||
1GILD.MI | GILEAD SCIENCES INC | 12.65 | 108.39B | ||
GIS.DE | GILEAD SCIENCES INC | 12.52 | 107.23B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 98.55B | ||
1REGN.MI | REGENERON PHARMACEUTICALS | 11.05 | 52.64B | ||
ARGX.BR | ARGENX SE | 104.42 | 30.29B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 20.04B | ||
IDP.DE | BIOGEN INC | 7.52 | 15.50B | ||
0QF.DE | MODERNA INC | N/A | 8.54B | ||
1MRNA.MI | MODERNA INC | N/A | 8.14B | ||
BIO.DE | BIOTEST AG | 65.54 | 1.69B |
genOway SA engages in the development of genetically modified mouse, rat, and cellular models for biopharmaceutical and research companies. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2007-05-04. The firm offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s clients include multinational biopharmaceutical companies, such as Roche, Novartis and Servier, as well as universities and research institutes, notably Boston University, University of Tokyo, Johann Wolfgang Goethe University Hospital Frankfurt and Centre National de Genotypage.
GENOWAY SA
Technopark 2, 31 Rue Saint Jean-de-Dieu
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 128
Phone: 33437654100
The current stock price of ALGEN.PA is 3.0595 EUR. The price increased by 1.98% in the last trading session.
The exchange symbol of GENOWAY SA is ALGEN and it is listed on the Euronext Paris - Matif exchange.
ALGEN.PA stock is listed on the Euronext Paris - Matif exchange.
9 analysts have analysed ALGEN.PA and the average price target is 6.02 EUR. This implies a price increase of 96.7% is expected in the next year compared to the current price of 3.0595. Check the GENOWAY SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GENOWAY SA (ALGEN.PA) has a market capitalization of 29.00M EUR. This makes ALGEN.PA a Nano Cap stock.
GENOWAY SA (ALGEN.PA) currently has 128 employees.
GENOWAY SA (ALGEN.PA) has a support level at 3.06 and a resistance level at 3.12. Check the full technical report for a detailed analysis of ALGEN.PA support and resistance levels.
The Revenue of GENOWAY SA (ALGEN.PA) is expected to grow by 18.41% in the next year. Check the estimates tab for more information on the ALGEN.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALGEN.PA does not pay a dividend.
The PE ratio for GENOWAY SA (ALGEN.PA) is 21.85. This is based on the reported non-GAAP earnings per share of 0.14 and the current share price of 3.0595 EUR. Check the full fundamental report for a full analysis of the valuation metrics for ALGEN.PA.
ChartMill assigns a technical rating of 2 / 10 to ALGEN.PA. When comparing the yearly performance of all stocks, ALGEN.PA is a bad performer in the overall market: 88.35% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to ALGEN.PA. While ALGEN.PA has a great profitability rating, there are some minor concerns on its financial health.
Over the last trailing twelve months ALGEN.PA reported a non-GAAP Earnings per Share(EPS) of 0.14. The EPS decreased by -20.89% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 5.86% | ||
ROA | 3.96% | ||
ROE | 7.06% | ||
Debt/Equity | 0.26 |
ChartMill assigns a Buy % Consensus number of 87% to ALGEN.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -20% and a revenue growth 18.41% for ALGEN.PA